NANOVALENT PHARMACEUTICALS INC — Federal Contracts, Awards & Government Contractor Profile

About NANOVALENT PHARMACEUTICALS INC

NanoValent Pharmaceuticals is a privately held company focused on developing novel targeted therapies for hard-to-treat cancers and hematological malignancies using its proprietary Hybrid Polymerized Liposomal Nanoparticle (HPLN) platform technology. The company is advancing nano-ADC-like Targeted Nanospheres (nADC/TNS) to improve the delivery, safety, and efficacy of anticancer therapeutics.

Development of novel format conjugates called nano-ADC-like Targeted Nanospheres (nADC/TNS)Utilization of Hybrid Polymerized Liposomal Nanoparticle (HPLN) platform technologyAbility to cross the blood-brain barrier (BBB) for applications beyond oncologyCreation of tumor-specific targeted therapies with higher drug-to-antibody ratios (DAR) than traditional ADCsDevelopment of investigational drug candidates for various cancers including glioblastoma, pancreatic, ovarian, and Ewing Sarcoma

Is this your company?

Claim NANOVALENT PHARMACEUTICALS INC to unlock the federal & state contracts GovIntel's AI has matched to you right now — plus your own scored past-performance, who you're up against, and who's risky to team with.

Claim NANOVALENT PHARMACEUTICALS INC & see your matches

Free to claim. Takes about a minute.

Data compiled from public government sources including SAM.gov, USAspending.gov, and state procurement records. Last verified against federal award records. Inaccurate, or want this page removed? Request a correction or removal.